octane news
Kingston, Ontario, 15 December 2020 – Octane Medical Group has expanded its state-of-the-art facility in Kingston, Ontario Canada.
The 40,000-square-foot building, which Octane purchased in 2011, houses the company’s head office and features regulated biolabs for biomaterial and biologics discovery programs including cell therapy research and development, a fully equipped cleanroom and manufacturing floor for production of medical devices, biomaterials, instrumentation and disposable components for clinical systems.
“With our new facility, we are well-positioned for further growth in our multiple business units and for continued advances in our regenerative medicine innovations”, says Octane CEO Tim Smith. “It’s another big step forward in our journey.”
For press inquiries please contact Renee Thibodeau.
[email protected]
613-634-6345 x200
Cocoon™ is a patient-scale cell therapy system that forms the core of a series of versatile cell and tissue therapy production systems. Unlike other bioreactor systems, this platform integrates multiple steps, including upstream and downstream processing. From cell source isolation and cell expansion, through to cell collection, cell washing and final product formation – all in a closed, single-use disposable cassette
Coupled with advanced bioreactors, biosensor feedback and innovative cell scaffolds, this cell culture and tissue engineering platform opens up an array of clinical applications. Cocoon is an integrated turnkey production solution that can be configured as a compact but powerful system with a small footprint, or as a multi-patient system for ultra-efficient, enterprise-level deployment. Please read more about our game-changing innovations in regenerative medicine .
Kingston, Ontario, Canada / Melsungen, Germany, June 5th, 2024 – Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global orthobiologics business from its long-term partner B. Braun. The acquisition, consisting of the two companies TETEC AG in Germany and Aesculap Biologics, LLC. in the United States, establishes Octane as an international leader in regenerative medicine.
June 5, 2024
Kingston, Ontario, June 2, 2022 – Octane Exo Inc., an Octane Medical Group venture, has achieved a breakthrough in medical implant technology with Octane HyperPEEK, an advanced biocomposite proven to enhance bone regeneration with the goal of enhanced integration and stability.
March 2, 2022
Maine, USA, 18 March 2020 – Octane innovations in tissue engineering, personalized medicine and automated living implant production have earned one of the highest Edison Awards, winning Gold in the Medical / Dental Cellular Research category. The Gold award recognizes AUTOGRAFTA™ living graft technology and the ability to ...
March 18, 2020
Basel, Switzerland, 29 October 2018 – Lonza announced today the acquisition of a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane ...
October 29, 2018